662
Participants
Start Date
March 31, 2008
Primary Completion Date
July 31, 2009
Study Completion Date
October 31, 2010
MenACWY-CRM197 (two doses)
Two 0.5mL doses of MenACWY conjugate vaccine (MenACWY-CRM197) was administered by intramuscular injection.
MenC
One 0.5mL dose of MenC vaccine was administered by intramuscular injection.
PCV7
One 0.5mL dose of Pneumococcal 7-valent Conjugate Vaccine (PCV7) was administered by intramuscular injection.
DTPa-IPV-HepB-Hib
One 0.5mL dose of Combined Diphtheria-Tetanus-acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b (DTPa-IPV-HepB-Hib) vaccine was administered by intramuscular injection.
MenACWY-CRM197 (one dose)
One 0.5mL dose of MenACWY conjugate vaccine (MenACWY-CRM197) was administered by intramuscular injection.
Site 3, Berlin
Site 27, Berlin
Site 20, Berlin
Site 26, Berlin
Site 13, Berlin
Site 31, Berlin
Site 25, Berlin
Site 35, Hamburg
Site 21, Neumünster
Site 9, Neumünster
Site 32, Flensburg
Site 33, Glücksburg
Site 39, Eschwege
Site 28, Mainz
Site 44, Mainz
Site 22, Bad Kreuznach
Site 24, Balve
Site 16, Frankenthal
Site 6, Wiesloch
Site 4, Stuttgart
Site 19, Stuttgart
Site 10, Oberstenfeld
Site 15, Bönnigheim
Site 2, Kehl
Site 43, München-Ramersdorf
Site 30, Weilheim I OB
Site 42, Neuhaus am Rennweg
Site 38, Bad Lobenstein
Lead Sponsor
Novartis Vaccines
INDUSTRY